BR112015023635A2 - composições e métodos para construtos quiméricos de vírus da dengue em vacinas - Google Patents

composições e métodos para construtos quiméricos de vírus da dengue em vacinas

Info

Publication number
BR112015023635A2
BR112015023635A2 BR112015023635A BR112015023635A BR112015023635A2 BR 112015023635 A2 BR112015023635 A2 BR 112015023635A2 BR 112015023635 A BR112015023635 A BR 112015023635A BR 112015023635 A BR112015023635 A BR 112015023635A BR 112015023635 A2 BR112015023635 A2 BR 112015023635A2
Authority
BR
Brazil
Prior art keywords
vaccines
compositions
methods
dengue virus
chimeric dengue
Prior art date
Application number
BR112015023635A
Other languages
English (en)
Other versions
BR112015023635A8 (pt
BR112015023635B1 (pt
Inventor
Y Hung Claire
T Stinchcomb Dan
A Livengood Jill
M Kinney Richard
Original Assignee
Takeda Vaccines Inc
The Government Of The United States Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, The Government Of The United States Of America filed Critical Takeda Vaccines Inc
Priority to BR122021015502-0A priority Critical patent/BR122021015502B1/pt
Priority to BR122021015503-8A priority patent/BR122021015503B1/pt
Publication of BR112015023635A2 publication Critical patent/BR112015023635A2/pt
Publication of BR112015023635A8 publication Critical patent/BR112015023635A8/pt
Publication of BR112015023635B1 publication Critical patent/BR112015023635B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • C07K14/1816Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • C12N15/8613Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24162Methods of inactivation or attenuation by genetic engineering
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015023635-9A 2013-03-15 2014-03-12 Moléculas de polinucleotídeo que codificam uma cepa pdk-53 modificada do vírus dengue-2 vivo atenuado, cepa pdk-53 do vírus vivo atenuado dengue 2 modificada, polipeptídeos, vetor, composição farmacêutica, uso da mesma, composição imunogênica e kit BR112015023635B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122021015502-0A BR122021015502B1 (pt) 2013-03-15 2014-03-12 Molécula de polinucleotídeo que codifica uma quimera de ácido nucleico de dengue-1/dengue-2, molécula de polipeptídeo, quimera de dengue- 1/dengue-2, composição farmacêutica e seu uso, vetor, composição imunogênica, e kit
BR122021015503-8A BR122021015503B1 (pt) 2013-03-15 2014-03-12 Molécula de polinucleotídeo que codifica uma quimera de ácido nucleico de dengue-4/dengue-2, molécula de polipeptídeo, quimera dengue- 4/dengue-2, composição farmacêutica e seu uso, vetor, composição imunogênica, e kit

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
US61/800,204 2013-03-15
PCT/US2014/024603 WO2014150939A2 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (3)

Publication Number Publication Date
BR112015023635A2 true BR112015023635A2 (pt) 2018-06-05
BR112015023635A8 BR112015023635A8 (pt) 2021-12-14
BR112015023635B1 BR112015023635B1 (pt) 2023-07-25

Family

ID=

Also Published As

Publication number Publication date
PE20211814A1 (es) 2021-09-14
BR122021015503A2 (pt) 2021-12-14
SI4129330T1 (sl) 2024-02-29
US20140302088A1 (en) 2014-10-09
PT3539565T (pt) 2023-04-12
CA3177572A1 (en) 2014-09-25
TWI726312B (zh) 2021-05-01
AU2014235476A1 (en) 2015-09-24
ES2933970T3 (es) 2023-02-15
EP2968516A2 (en) 2016-01-20
EP4129330A1 (en) 2023-02-08
JP6818548B2 (ja) 2021-01-20
UY35489A (es) 2014-10-31
HRP20231581T1 (hr) 2024-03-15
NL301223I2 (nl) 2023-07-26
HK1220359A1 (zh) 2017-05-05
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
JP2016513970A (ja) 2016-05-19
NZ735336A (en) 2021-04-30
LT4129330T (lt) 2023-12-27
AU2019216724B2 (en) 2021-03-04
US20230181682A1 (en) 2023-06-15
ECSP23013715A (es) 2023-04-28
EP3689374B1 (en) 2022-11-02
PL3539565T3 (pl) 2023-09-25
CN113637086A (zh) 2021-11-12
TW201516147A (zh) 2015-05-01
KR20240014580A (ko) 2024-02-01
CN105451763A (zh) 2016-03-30
WO2014150939A2 (en) 2014-09-25
FIC20230021I1 (fi) 2023-06-27
PH12015502120A1 (en) 2016-01-25
SG11201507460PA (en) 2015-10-29
CN113637694A (zh) 2021-11-12
KR20160002780A (ko) 2016-01-08
KR20220054892A (ko) 2022-05-03
KR102389908B1 (ko) 2022-04-26
CN105451763B (zh) 2021-06-18
CR20150569A (es) 2016-04-01
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
NZ630869A (en) 2017-11-24
CA3166063A1 (en) 2014-09-25
CA3177574A1 (en) 2014-09-25
MX2023000353A (es) 2023-02-13
EP4183411A1 (en) 2023-05-24
BR112015023635A8 (pt) 2021-12-14
US9783579B2 (en) 2017-10-10
US10449231B2 (en) 2019-10-22
SG10201913387XA (en) 2020-02-27
DOP2015000232A (es) 2016-02-29
US20170290884A1 (en) 2017-10-12
US20220062375A1 (en) 2022-03-03
BR122021015502A2 (pt) 2021-12-14
FI3539565T3 (fi) 2023-04-19
PE20160027A1 (es) 2016-01-28
HUS2300022I1 (hu) 2023-08-28
CN113637693A (zh) 2021-11-12
US11931399B2 (en) 2024-03-19
WO2014150939A3 (en) 2014-12-31
MX2023000349A (es) 2023-04-24
MX2019003602A (es) 2022-06-27
MY187796A (en) 2021-10-24
CN111778263A (zh) 2020-10-16
AU2014235476B2 (en) 2019-05-16
DK4129330T3 (da) 2023-12-11
EP4129330B1 (en) 2023-09-06
TWI733646B (zh) 2021-07-21
EP3539565B1 (en) 2023-01-11
KR102626270B1 (ko) 2024-01-19
EP2968516B1 (en) 2022-01-12
TW202144573A (zh) 2021-12-01
JP2019146594A (ja) 2019-09-05
AU2019216724A1 (en) 2019-09-05
JP7050031B2 (ja) 2022-04-07
CA2903231A1 (en) 2014-09-25
AR095598A1 (es) 2015-10-28
MX2023000354A (es) 2023-02-13
TW201945545A (zh) 2019-12-01
SG10201913435TA (en) 2020-03-30
EP3539565A1 (en) 2019-09-18
AR123702A2 (es) 2023-01-04
US20200061151A1 (en) 2020-02-27
MX2015012893A (es) 2016-04-04
AU2019216724C1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
HUS2300022I1 (hu) Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
BR112015028459A2 (pt) composições e comestíveis
IL244081A0 (en) Preparations and methods for modulating RNA
BR302014001267S1 (pt) Configuração aplicada em liquidificador
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
BR112015023679A2 (pt) composições e métodos para imunoterapia
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
IL245173B (en) History of tyrosine and preparations containing them
BR112015017899A2 (pt) método e aparelho para serviços em nuvem para aprimorar experiência em banda larga
EP3008176A4 (en) COMPOSITIONS AND METHODS FOR REINFORCING THE VIRUS REPLICATION
DK2969005T3 (da) Attenuerede influenzavira og -vacciner
SG11201510617WA (en) Methods and compositions for dengue virus vaccines
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
DK3091857T3 (da) Sammensætninger med oksekødsaroma og fremstilling deraf
EP2956469A4 (en) METHODS AND COMPOSITIONS FOR CONCENTRATING PROTEINS
FR3007291B1 (fr) Composition cicatrisante et utlisation
CL2015002013A1 (es) Composición alimenticia que comprende desferricrisina
DK3057450T3 (da) Fødevaresammensætning
TH1501005277A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
UA27009S (uk) Обігрівач для ніг
BR302013004809S1 (pt) Configuração aplicada em churrasqueira
BR302013004538S1 (pt) Configuração aplicada em churrasqueira
BR302014001313S1 (pt) Configuração aplicada em liquidificador
TH1401007607A (th) องค์ประกอบอาหารชนิดเข้มข้นในรูปของเจล

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: TAKEDA VACCINES, INC (US) ; THE GOVERNMENT OF THE UNITED STATES OF AMERICA (US)

Owner name: TAKEDA VACCINES, INC (US) ; THE GOVERNMENT OF THE

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023006566-2 PROTOCOLO 870230029438 EM 06/04/2023 18:03.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS